X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (320) 320
ophthalmology (259) 259
humans (244) 244
bevacizumab (170) 170
administration, topical (161) 161
male (156) 156
female (138) 138
animals (103) 103
endothelial growth-factor (102) 102
angiogenesis inhibitors - administration & dosage (99) 99
vascular endothelial growth factor a - antagonists & inhibitors (95) 95
middle aged (93) 93
neovascularization (93) 93
angiogenesis (88) 88
aged (86) 86
eye diseases (84) 84
topical bevacizumab (82) 82
corneal neovascularization (75) 75
macular degeneration (70) 70
corneal neovascularization - drug therapy (68) 68
ranibizumab (68) 68
vascular endothelial growth factor (68) 68
angiogenesis inhibitors - therapeutic use (67) 67
adult (57) 57
sense organs (56) 56
avastin (55) 55
treatment outcome (55) 55
cornea (52) 52
genetic structures (51) 51
disease models, animal (50) 50
inhibition (46) 46
subconjunctival bevacizumab (46) 46
pharmacology & pharmacy (45) 45
antibodies, monoclonal, humanized - administration & dosage (44) 44
injection (43) 43
prospective studies (42) 42
intravitreal injections (41) 41
aged, 80 and over (40) 40
surgery (40) 40
ophthalmic solutions (39) 39
antibodies, monoclonal, humanized (38) 38
rabbits (38) 38
efficacy (36) 36
therapy (34) 34
analysis (32) 32
antibodies, monoclonal - administration & dosage (32) 32
vegf (32) 32
intravitreal injection (31) 31
mice (31) 31
corneal neovascularization - pathology (30) 30
endophthalmitis (30) 30
eye (30) 30
care and treatment (29) 29
follow-up studies (29) 29
macular edema - drug therapy (29) 29
antibodies, monoclonal, humanized - therapeutic use (28) 28
inflammation (28) 28
rats (28) 28
medicine & public health (27) 27
retrospective studies (27) 27
expression (26) 26
intravitreal bevacizumab (26) 26
macular degeneration - drug therapy (26) 26
risk factors (26) 26
triamcinolone acetonide (26) 26
angiogenesis inhibitors - adverse effects (25) 25
diabetic retinopathy (25) 25
drug delivery systems (25) 25
drug therapy (25) 25
eye drops (25) 25
ophthalmic solutions - administration & dosage (25) 25
injections (24) 24
optical coherence tomography (24) 24
visual acuity - physiology (24) 24
visual acuity (23) 23
injections, intraocular (22) 22
medicine, research & experimental (22) 22
retina (22) 22
angiogenesis inhibitors (21) 21
endothelial growth factors (21) 21
article (20) 20
photodynamic therapy (20) 20
prevention (20) 20
health aspects (19) 19
pharmacokinetics (19) 19
vascular endothelial growth factor a - metabolism (19) 19
cancer (18) 18
conjunctiva - drug effects (18) 18
cornea - drug effects (18) 18
corneal neovascularization - metabolism (18) 18
diabetic macular edema (18) 18
intravitreal injections - adverse effects (18) 18
lymphangiogenesis (18) 18
research (18) 18
subconjunctival (18) 18
abridged index medicus (17) 17
angiogenesis inhibitors - pharmacology (17) 17
cataract-surgery (17) 17
drug therapy, combination (17) 17
edema (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pharmaceutical Research, ISSN 0724-8741, 6/2018, Volume 35, Issue 6, pp. 1 - 13
Permeation studies, with near infrared (NIR) light and anti-aggregation antibody formulation, were used to investigate the in vitro permeation of bevacizumab,... 
Biochemistry, general | Biomedical Engineering | Biomedicine | photokinetic | aflibercept | permeation | Pharmacy | bevacizumab | Medical Law | sclera | Pharmacology/Toxicology | ranibizumab | PHOTOBIOMODULATION | MACROMOLECULES | VISUAL IMPAIRMENT | MACULAR DEGENERATION | VEGF THERAPY BEVACIZUMAB | CHEMISTRY, MULTIDISCIPLINARY | CORNEAL NEOVASCULARIZATION | TOPICAL BEVACIZUMAB | PHARMACOLOGY & PHARMACY | AGENTS | IONTOPHORETIC TRANSPORT | EYE DROPS | Sclera - radiation effects | Administration, Ophthalmic | Bevacizumab - administration & dosage | Ranibizumab - pharmacokinetics | Sclera - metabolism | Humans | Bevacizumab - pharmacokinetics | Angiogenesis Inhibitors - pharmacokinetics | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - drug therapy | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Angiogenesis Inhibitors - administration & dosage | Permeability - radiation effects | Infrared Rays | Recombinant Fusion Proteins - pharmacokinetics | Ranibizumab - administration & dosage | Recombinant Fusion Proteins - administration & dosage | Macular Degeneration - pathology | Viral antibodies | Drugs | Drug delivery systems | Biological products | Endothelial growth factors | Analysis | Ophthalmic drugs | Antibodies | Angiogenesis inhibitors | Vehicles | Light irradiation | Light emitting diodes | Drug delivery | Liquid chromatography | High-performance liquid chromatography | Light effects | Wavelength | Bevacizumab | Pulse rate | Pulse duration | Penetration | Irradiation | Infrared radiation | Pulse duration modulation | Vascular endothelial growth factor | Enzyme-linked immunosorbent assay | Research Paper
Journal Article
International Ophthalmology, ISSN 0165-5701, 1/2019, Volume 39, Issue 1, pp. 55 - 62
To investigate the effectiveness of combined photodynamic therapy with verteporfin and intrastromal injection of bevacizumab for the treatment of corneal... 
Photodynamic therapy | Ophthalmology | Intrastromal injection of bevacizumab | Medicine & Public Health | Steven–Johnson syndrome | Corneal neovascularization | MANAGEMENT | VEGF | TOXIC EPIDERMAL NECROLYSIS | GRADING SYSTEM | Steven-Johnson syndrome | TOPICAL BEVACIZUMAB | INJECTION | ACUTE OCULAR MANIFESTATIONS | OPHTHALMOLOGY | COMPLICATIONS | SUBCONJUNCTIVAL BEVACIZUMAB | OCCLUSION | Stevens-Johnson Syndrome - drug therapy | Follow-Up Studies | Photochemotherapy - methods | Corneal Neovascularization - drug therapy | Humans | Middle Aged | Male | Corneal Stroma | Dose-Response Relationship, Drug | Photosensitizing Agents - administration & dosage | Angiogenesis Inhibitors - administration & dosage | Adult | Female | Drug Therapy, Combination | Verteporfin - administration & dosage | Corneal Neovascularization - etiology | Bevacizumab - administration & dosage | Stevens-Johnson Syndrome - complications | Slit Lamp Microscopy | Treatment Outcome | Visual Acuity | Stevens-Johnson Syndrome - diagnosis | Injections | Corneal Neovascularization - diagnosis | Aged | Medical colleges | Verteporfin | Neovascularization | Photochemotherapy | Cancer | Cornea | Regression | Blood vessels | Visual acuity | Injection | Patients | Vascularization | Acuity | Bevacizumab | Eye | Lasers | Eye (anatomy) | Photographs | Prednisolone | Intraocular pressure | Index Medicus
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2017, Volume 12, Issue 1, pp. e0169675 - e0169675
Journal Article
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 2013, Volume 156, Issue 3, pp. 616 - 622.e3
Journal Article
Experimental Eye Research, ISSN 0014-4835, 08/2019, Volume 185, pp. 107697 - 107697
Corneal neovascularization (CNV) is associated with different ocular pathologies, including infectious keratitis, trachoma or corneal trauma. Pharmacological... 
Nanoparticles | Human serum albumin | Pegylated | Ocular delivery | Corneal neovascularization | Bevacizumab | DEXAMETHASONE | SUBCONJUNCTIVAL | EFFICACY | VEGF | PREVENTION | DELIVERY | TOPICAL BEVACIZUMAB | OPHTHALMOLOGY | AFLIBERCEPT | Index Medicus
Journal Article